Tumour therapy with Vinca alkaloids targeted by a hybrid-hybrid monoclonal antibody recognising both CEA and Vinca alkaloids.
The functional properties of a hybrid-hybrid monoclonal antibody (MAb) recognising both CEA and Vinca alkaloids have been explored in vivo in nude mice xenografted with MAWI, a human colorectal tumour. The hybrid-hybrid MAb localises specifically onto CEA-expressing tumour tissue and, furthermore, is able to target Vinca alkaloids to tumour. Under the influence of the hybrid-hybrid MAb a profound change in the bio-distribution patterns of the Vinca alkaloids is observed. Therapeutic data produced in this in vivo model indicates that treatment with Vinca alkaloids in conjunction with hybrid-hybrid MAb is significantly more effective in suppressing tumour growth of established tumour xenografts than the Vincas when given as free drug.
Corvalan
J R
JR
Lilly Research Centre, Windlesham, Surrey, UK.
Smith
W
W
Gore
V A
VA
D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D002272:Carcinoembryonic Antigen / Q000276:immunology*; D051379:Mice; D009374:Neoplasms, Experimental / Q000188:drug therapy*; D014748:Vinca Alkaloids / Q000008:administration & dosage* / Q000276:immunology
D000911:Antibodies, Monoclonal; D002272:Carcinoembryonic Antigen; D014748:Vinca Alkaloids